These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31456522)

  • 1. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.
    Shao YT; Ma L; Zhang TH; Xu TR; Ye YC; Liu Y
    Curr Top Med Chem; 2019; 19(23):2143-2157. PubMed ID: 31456522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of the oncogenic
    Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
    Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
    [No Abstract]   [Full Text] [Related]  

  • 5. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
    Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
    Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
    He H; Xu C; Cheng Z; Qian X; Zheng L
    Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
    Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
    Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
    Hoo WPY; Siak PY; In LLA
    Curr Top Med Chem; 2019; 19(23):2158-2175. PubMed ID: 31483231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
    Kim J
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
    McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
    Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
    Zhu Z; Xiao S; Hao H; Hou Q; Fu X
    Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
    Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
    Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethal Vulnerabilities in
    Aguirre AJ; Hahn WC
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.